EGFR and non-small cell lung carcinoma: Recent advancements in the NSCLC adjuvant treatment setting, the molecular diagnostics for EGFR and ALK in the early stage, indeed necessary to exclude targetable alterations to pave the way to proceed with immunotherapy based on PD-L1 expressors.